Measurement of nasal bone length at 11–14 weeks of pregnancy and its potential role in Down syndrome risk assessment

Objectives To assess the feasibility of measuring nasal bone length in first‐trimester pregnancy and to confirm if the absence of a fetal nasal bone is a marker for Down syndrome. Methods Fetal nasal bone assessment was attempted in 1089 consecutive singleton pregnancies between 11 and 14 weeks'...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Ultrasound in obstetrics & gynecology 2003-07, Vol.22 (1), p.36-39
Hauptverfasser: Orlandi, F., Bilardo, C. M., Campogrande, M., Krantz, D., Hallahan, T., Rossi, C., Viora, E.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Objectives To assess the feasibility of measuring nasal bone length in first‐trimester pregnancy and to confirm if the absence of a fetal nasal bone is a marker for Down syndrome. Methods Fetal nasal bone assessment was attempted in 1089 consecutive singleton pregnancies between 11 and 14 weeks' gestation. All ultrasound examinations were performed transabdominally in three separate centers. If the nasal bone was present, nasal bone length was measured. Results Nasal bone assessment was successfully achieved in 1027 of 1089 (94.3%) ultrasound examinations. Within this group nasal bone was absent in 10 of 1000 (1.0%) unaffected cases, 10 of 15 (66.7%) Down syndrome cases and 5 of 12 (41.7%) cases with other pathological conditions. Regression analysis showed a significant increase (P < 0.0001) in nasal bone length from 2.48 mm at a crown–rump length of 45 mm to 3.12 mm at a crown–rump length of 84 mm. The nasal bone length in the five cases of Down syndrome in which the nasal bone was present was less than the median measurement of unaffected cases. Using modeling, the combination of nasal bone with maternal age, nuchal translucency, free beta‐human chorionic gonadotropin (hCG) and pregnancy associated plasma protein‐A (PAPP‐A) achieved a detection rate of 95% with a false‐positive rate of 2.9%. At a fixed 1% false‐positive rate, the detection rate was 91%. Conclusions Absence of the nasal bone can be used as a marker for Down syndrome in the first trimester of pregnancy. Inclusion of the nasal bone in the current first‐trimester screening protocol along with nuchal translucency, free beta‐hCG and PAPP‐A can achieve high detection at a very low false‐positive rate. Large datasets are needed to confirm whether the measurement of nasal bone length provides additional benefits beyond the assessment of the presence or absence of the nasal bone. Copyright © 2003 ISUOG. Published by John Wiley & Sons, Ltd.
ISSN:0960-7692
1469-0705
DOI:10.1002/uog.167